# A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

Source: https://onco.cc/trials/nct06382116/  
OnCo record `nct06382116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Izalontamab brengitecan, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) is a phase 3 interventional study registered as NCT06382116 by Sichuan Baili Pharmaceutical Co., Ltd., with 432 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-08. Interventions recorded: BL-B01D1, Pemetrexed+Cisplatin or Carboplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06382116
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 432

## Sources

- ClinicalTrials.gov NCT06382116: https://clinicaltrials.gov/study/NCT06382116

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06382116.json